Welcome to our dedicated page for AMRS news (Ticker: AMRS), a resource for investors and traders seeking the latest updates and insights on AMRS stock.
Amyris, Inc. (AMRS) is frequently featured in news coverage for its activities as a vertically integrated synthetic biology company focused on sustainable ingredients produced via precision fermentation. Company announcements highlight developments across its Lab-to-Market™ technology platform, industrial biomanufacturing assets, strategic partnerships, and financial and operational restructuring efforts.
News about Amyris often covers its strategic transformation initiatives, including programs aimed at cost reduction, portfolio simplification, and changes to its capital structure and liquidity. The company has publicly discussed a transformation program supported by external advisors, as well as the establishment of internal governance structures to oversee these efforts. A significant news event was the commencement of voluntary Chapter 11 proceedings by Amyris and certain domestic subsidiaries, described as a step to facilitate an operational and financial restructuring centered on its core sustainable ingredients business.
Investors and observers can also find updates on Amyris’ industrial biotechnology operations, such as its precision fermentation plant in Barra Bonita, Brazil. Recent news includes Amyris taking full ownership of this plant, investing in additional fermentation capacity, and winding down a joint venture while retaining manufacturing assets and royalty interests related to specific fermented ingredients.
Another recurring theme in Amyris news is the formation and evolution of strategic partnerships and licensing agreements. Press releases describe exclusive licenses for cosmetic ingredients, long-term manufacturing agreements, and collaborations for sustainable squalene and fermented sweetener technologies. Earnings updates and revenue guidance communications provide additional context on how these partnerships, ingredient sales, and technology access activities fit into the company’s broader strategic agenda.
This news page aggregates such company-issued releases and related coverage, offering a centralized view of key developments in Amyris’ synthetic biology, fermentation, partnership, and restructuring activities over time.
Amyris, Inc. (Nasdaq: AMRS) announced a new partnership with Jonathan Van Ness to launch a clean haircare brand, aiming to revolutionize the industry with sustainable, effective products. Expected to launch in summer 2021, the brand will utilize Amyris's proprietary hemi-squalane ingredient for enhanced hair health across all textures. This move expands Amyris's footprint in the clean beauty market, which represents a significant segment of the $300 billion beauty industry, furthering its commitment to inclusivity and environmentally friendly products.
Amyris, Inc. (Nasdaq: AMRS) announced its entry into the Greater China market with its Biossance Clean Beauty brand, partnering with SuperOrdinary Group. This collaboration positions Biossance within one of the fastest-growing beauty markets where consumers prioritize sustainable products. The partnership aims to leverage SuperOrdinary's expertise in establishing leading brands in China. Amyris expects significant growth, citing strong fourth-quarter sales and aiming for sales revenue equivalent to all of 2019. This strategic move aligns with the increasing demand for clean beauty products in China.
Amyris, Inc. (Nasdaq: AMRS) has achieved the Bonsucro Chain of Custody Certification, ensuring sustainable sugarcane supply chain practices from farmer to end user. This certification underscores Amyris' commitment to delivering clean and sustainable products in the Clean Health and Beauty sectors, aligning with ethical and fair-trade practices. CEO John Melo emphasized that consumer demand for sustainably sourced products has surged, further enhancing Amyris’ growth potential and strengthening partnerships. This makes Amyris a pioneer as the first biotech company to receive this certification, indicating significant industry differentiation.
Amyris, Inc. (Nasdaq: AMRS), a leader in synthetic biotechnology, has completed a strategic transaction with DSM Nutritional Products Ltd valued at $50 million. This deal involves licensing rights for Farnesene to Givaudan for a specialty ingredient. Of the total amount, $30 million is due by December 30, 2020, with further payments scheduled for the first quarter of 2021 and potential milestone payments thereafter. This is the first of three anticipated transactions as per management's recent investor event on December 15, 2020.
Amyris, a synthetic biotechnology firm listed on Nasdaq as AMRS, successfully hosted the first session of its virtual investor mini-series, titled "Delivering on the Promise of Synthetic Biology." This session, held on December 15, 2020, featured nearly 300 participants and included a business update, technology presentation, and Q&A. CEO John Melo discussed strategic transactions and future outlook, while SVP Sunil Chandran showcased the company's technology platform. Future sessions are planned, focusing on the Consumer and Ingredients portfolios in Q1 2021.
Summary not available.
Amyris, in a recent announcement, revealed the launch of a virtual investor mini-series titled "Delivering on the Promise of Synthetic Biology". The first webinar, Science and Technology, Sustainable Solutions for a Healthier Planet, is scheduled for December 15, 2020, at 1:00 PM ET. The initiative aims to educate investors on Amyris's operations and advancements, particularly in sustainable ingredients for health and beauty markets. Future sessions will cover the Consumer and Ingredients portfolios, enhancing investor engagement.
Amyris, Inc. (Nasdaq: AMRS) reported record sales revenue from its consumer brands during Black Friday, with sales revenue tripling compared to 2019. The Biossance brand alone surpassed $1 million in sales, driven by a 129% increase in customers. Notably, 57% of sales came from first-time customers. Overall, Amyris's fourth quarter is expected to match its total sales from 2019. The company has invested in its digital infrastructure to meet rising online shopping demands, ensuring efficient supply chain and fulfillment capabilities.
Amyris, a leading synthetic biotechnology company based in Emeryville, California, will present at Evercore ISI's 3rd Annual HealthCONx Conference on December 3, 2020, at 2:40 p.m. ET. The presentation will highlight the company's innovations in sustainable and natural ingredients for Clean Health and Beauty markets. A live webcast and replay will be available on the company's Investor Relations website. Amyris is known for its three consumer brands: Biossance, Pipette, and Purecane, all built on its No Compromise promise of clean ingredients.
Amyris, Inc. (Nasdaq: AMRS) reported a strong Q3 2020, with Product Revenue reaching $31 million, up 58% year-over-year. Consumer sales surged by 203%, contributing to an expanded Gross Margin of 41%. Adjusted EBITDA improved to -$33 million, a $10 million enhancement from last year, as cash operating expenses decreased by 10% to $43 million. The company anticipates a profitable 2021, driven by successful strategic initiatives and high growth in consumer brands. However, the ongoing impact of COVID-19 adds uncertainty to the future financial outlook.
